Question: Drugs targeting Gene Fusions
0
gravatar for Ron
7 months ago by
Ron980
United States
Ron980 wrote:

Hello ,

I wanted to know if gene fusions from RNAseq data can be said druggable based on one of the genes being druggable or it has to be druggable as a fusion ? I would like to look into the drugs that bind to the genes from fusions,so which one would be the right way to look into the data.

This resource has drugs interacting with gene fusions themselves. http://depo-dinglab.ddns.net/

If a fusion has to be druggable, are there more such resources of the known interactions? For drug- gene interactions I found this really good resource . http://dgidb.org/getting_started

Thanks

Ron

rna-seq next-gen • 311 views
ADD COMMENTlink modified 7 months ago by zepper40 • written 7 months ago by Ron980
1
gravatar for zepper
7 months ago by
zepper40
zepper40 wrote:

Hello Ron,

I think this very much depends on your definition of druggable and the mode of action of the drug in question, so I would be careful to generalize here.

Consider for example MLL-fusions, a well known oncogene in hematopoietic malignancies (nicely reviewed e.g. by Robert Slany PMID 26923329). There are several known fusion partners and 70 something breakpoints in the gene, so some fusions will retain more or less of the MLL protein than others. Just because a drug will target a specific MLL fusion doesn't mean it will target all.

Another example that comes to my mind is resistance to Imatinib treatment due to activating mutations in the tyrosine kinase c-Kit (see e.g Growney et al. PMID 15790786), so even in the case of just a single gene instead of a fusion it isn't guaranteed that a drug that nominally targets that gene will work for an individual patient.

Best Matthias

ADD COMMENTlink written 7 months ago by zepper40

So it is best to look at drug interactions with the gene fusion themselves ? I mean , A drug that would work for lets say ERBB2--CDK12 fusion would not work for ERBB2--PGAP3 fusion ? Or it can be considered druggable , based on how the gene fusion product is ?

On the contrary, it seems NTRK fusions and FGFR fusions which got recently approved drugs target all the fusions involving these genes?

ADD REPLYlink modified 6 months ago • written 6 months ago by Ron980
Please log in to add an answer.

Help
Access

Use of this site constitutes acceptance of our User Agreement and Privacy Policy.
Powered by Biostar version 2.3.0
Traffic: 1601 users visited in the last hour